Pioglitazone HCl

Catalog No.S2046 Synonyms: AD-4833, U-72107E

For research use only.

Pioglitazone HCl (AD-4833, U-72107E) is an inhibitor of cytochrome P450 (CYP)2C8 and CYP3A4 enzymes. Pioglitazone HCl inhibits CYP2C8, CYP3A4 and CYP2C9 with Ki of 1.7 μM, 11.8 μM and 32.1 μM, respectively. Pioglitazone HCl is also a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist with EC50 of 0.93 μM and 0.99 μM for human PPARγ and mouse PPARγ, respectively. Pioglitazone HCl inhibits mitochondrial iron uptake, lipid peroxidation, and subsequent ferroptosis.

Pioglitazone HCl Chemical Structure

CAS No. 112529-15-4

Selleck's Pioglitazone HCl has been cited by 10 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective P450 (e.g. CYP17) Inhibitors

Other P450 (e.g. CYP17) Products

Biological Activity

Description Pioglitazone HCl (AD-4833, U-72107E) is an inhibitor of cytochrome P450 (CYP)2C8 and CYP3A4 enzymes. Pioglitazone HCl inhibits CYP2C8, CYP3A4 and CYP2C9 with Ki of 1.7 μM, 11.8 μM and 32.1 μM, respectively. Pioglitazone HCl is also a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist with EC50 of 0.93 μM and 0.99 μM for human PPARγ and mouse PPARγ, respectively. Pioglitazone HCl inhibits mitochondrial iron uptake, lipid peroxidation, and subsequent ferroptosis.
Targets
Ferroptosis [8] hPPARγ [1]
(Cell-free assay)
rPPARγ [6]
(Cell-free assay)
CYP2C8 [7]
(Cell-free assay)
CYP3A4 [7]
(Cell-free assay)
Click to View More Targets
0.93 μM(EC50) 0.99 μM(EC50) 1.7 μM(Ki) 11.8 μM(Ki)
In vitro

Pioglitazone inhibits LPS-induced iNOS expression and NO generation, and inhibition of iNOS is sufficient to protect dopaminergic neurons against LPS insult. Pioglitazone protects dopaminergic neurons against LPS insult at least via inhibiting iNOS expression and NO generation, which is potentially mediated via inhibition of p38 MAPK activity. Pioglitazone inhibits LPS-induced phosphorylation of p38 MAPK. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
COS cells MYTGeY5kfGmxbjDhd5NigQ>? NV:xe5J7XHKjboPjdolxfGmxbnHsJIFkfGm4YYTpc44hcW5iQ1;TJINmdGy|IHX4dJJme3OrbnegVHBCWiCpYX3tZUBidmRiUmjSJIFteGijOzD2ZYx2\XNiaX6geIhmKHCjcnXueIhme2W|IHnu[Ilk[XSnczC5OUUh[2:wZnnk[Y5k\SCrboTldpZidCxiRVO1NF0xNjR7IN88US=> NHj3OJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUmwOlI6Oyd-MUG5NFYzQTN:L3G+
HepG2 cells MmfTSpVv[3Srb36gZZN{[Xl? MX;Q[ZJwgGm|b33lJJBzd2yrZnXyZZRweiCjY4TpeoF1\WRicnXj[ZB1d3JiZ3HtcYEh[WexbnnzeIlkKGGldHn2bZR6KGmwIFjldGczKGOnbHzzMEBGSzVyPUeuOkDPxE1? M1:3SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyN{G0OVA{Lz5zMEexOFUxOzxxYU6=
CV-1 MXfGeY5kfGmxbjDhd5NigQ>? NHTQeodKdiC4aYTyc{B1emGwc3PybZB1cW:wYXygZYN1cX[jdHnvckBw\iCSZYLvfIl{d22nIIDyc4xq\mW{YYTvdkBi[3SrdnH0[YQhemWlZYD0c5Ih\2GvbXGgLHBRSVJrIHX4dJJme3OnZDDpckBEXi1zIHPlcIx{NCCHQ{WwQVAvPjoQvF2u NGDSO409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96NUe2PVA4Lz56NUe2PVA4RC:jPh?=
3T3-L1 NWTofpZyTnWwY4Tpc44h[XO|YYm= MkW4SYZn\WO2aY\lJINwdmOnboTyZZRqd25iZn;yJFUxLSCnbnjhcoNmdWWwdDDv[kBqdnO3bHnuMYlv\HWlZXSgeJJq\2y7Y3XybYRmKGGlY4XteYxifGmxbjDpckA{XDNvTEGgZ4VtdHNuIFXDOVA:OC5zNt88UU4> Mlv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTV7OUK0NUc,QTV7OUK0NVww[T5?
CV-1 NV7jXpk1TnWwY4Tpc44h[XO|YYm= MYHBZ5RqfmG2aX;uJI9nKHCncn;4bZNwdWVicILvcIln\XKjdH;yJIFkfGm4YYTl[EBz\WOncITvdkBo[W2vYTDt[YF{fXKnZDDifUBqdmS3Y4Tpc44hd2ZiNUClJI9nKG2jeHnteY0h[WytYXzpcoUheGixc4DoZZRie2ViYXP0bZZqfHluIITyZY5{\mWldHnvckBie3OjeTDpckBEXi1zIHPlcIx{NCCHQ{WwQVAvPTh6OEVOwG0v NV7KRld2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUizOlYzOCd-OUizOlYzODxxYU6=
CV-1 NVPHO|VJTnWwY4Tpc44h[XO|YYm= MVLNZZhqdWGuIILldI9zfGW{IHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWGW{b4jpd49u\SCycn;sbYZmemG2b4KgZYN1cX[jdHXkJJJm[2WydH;yJIdidW2jIFfhcFQh[2irbXXybYMhcW5idILhcpNq\W62bImgeJJidnOoZXP0[YQhS1ZvMTDj[YxteyCkeTDmeY5kfGmxbnHsJIF{e2G7LDDFR|UxRTBwNUlOwG0v M3\YZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzN{KwPFU1Lz5zMUeyNFg2PDxxYU6=
HEK293 M{\DO2Z2dmO2aX;uJIF{e2G7 MVrB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDy[YNmeHSxcjDpcpRmemGldHnvckB4cXSqIIP0[ZJwcWRicnXj[ZB1d3JiY3;hZ5RqfmG2b4KtNUBjgSCHWV\QJIJie2WmIILldI9zfGW{IHflcoUh[XO|YYm= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjZ6MEG1PUc,OTZ4OECxOVk9N2F-
HEK293 MYnGeY5kfGmxbjDhd5NigQ>? MVzB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDy[YNmeHSxcjDpcpRmemGldHnvckB4cXSqIILleIlvd2mmIGitdoVk\XC2b4KgZYxxcGFiYomgSXlHWCCkYYPl[EBz\XCxcoTldkBo\W6nIHHzd4F6 MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjZ6MEG1PUc,OTZ4OECxOVk9N2F-
CV1 NFrUS3VHfW6ldHnvckBie3OjeR?= MWHUdoFve2GldHn2ZZRqd25ib3[gVHBCWmejbX3hJIlvKEOYMTDj[YxteyxiRVO1NF0xNjV3zszNMi=> Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6MkG3OlkoRjF4OEKxO|Y6RC:jPh?=
Cos7 MoDISpVv[3Srb36gZZN{[Xl? MnvVNVQhcHK| NYXxdYNWXHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJHBRSVKpYX3tZUBNSkRiZYjwdoV{e2WmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEOxc{egZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDmeZNm\CCJQVy0MWRDTCCjZoTldkAyPCCqcoOgZpkhTHWjbD3HcI8hVHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwM988UU4> M3rUUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C3PVgyLz5{MEOwO|k5OTxxYU6=
3T3L1 M2G0OmZ2dmO2aX;uJIF{e2G7 NGXSNFMyODBidX3vcE9N NV\XSog2UW6lcnXhd4UhcW5iUGDBVodidW2jIH3SUmEhdGW4ZXzzJIlvKG2xdYPlJFNVO0xzIHPlcIx{KGG2IEGwNEB2dW:uL1ygZpkhWlRvUFPS MmWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB|OUK2OFUoRjJyM{myOlQ2RC:jPh?=
CHO MV\GeY5kfGmxbjDhd5NigQ>? MUXBZ5RqfmG2aX;uJI9nKEejbESteIFo\2WmIHj1cYFvKFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkG0{txONg>? Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4NU[0PVQoRjJyNkW2OFk1RC:jPh?=
HEK293T MVjGeY5kfGmxbjDhd5NigQ>? MUixJJVO MnLENlQhcHK| NET1c5JR[XK2aXHsJIFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hMWxDTCCneIDy[ZN{\WRiaX6gTGVMOjl|VDDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhemWlZYD0c5IhfHKjboPhZ5RqfmG2aX;uJIF1KDFidV2gZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> M2H6NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEOwNlY{Lz5{MUCzNFI3OzxxYU6=
COS-1 M1e0SWZ2dmO2aX;uJIF{e2G7 NEDWbHZC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJGNQWy1zIHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiR3HsOEBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MD6zPe69VS5? MlLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzM{C2OFkoRjJzMUOwOlQ6RC:jPh?=
CHO MUHGeY5kfGmxbjDhd5NigQ>? M1PMUlI1KGi{cx?= NFLhN5RR[XK2aXHsJIFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDHZYw1NXKnc4DvcpNqfmVibIXjbYZmemG|ZTDy[ZBwenSncjDwcIF{dWmmIHHmeIVzKDJ2IHjyd{BjgSC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTB;MD6zPe69VS5? NV;mfWlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|c5PzVpPkKxN|c4QDd3PD;hQi=>
COS7 M{HzPWZ2dmO2aX;uJIF{e2G7 NGHGWotOd2S3bHH0bY9vKG:oIHj1cYFvKFCSQWLnZY1u[S2OQlSg[ZhxemW|c3XkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV|ch[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBI[Wx2IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZidILhcpNi[3SrdnH0bY9vKGGldHn2bZR6KGK7IHz1Z4ln\XKjc3WgZZN{[XluIFXDOVA:OC5|zszNMi=> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh5M{C3NEc,OjF6N{OwO|A9N2F-
Sf21 MXzGeY5kfGmxbjDhd5NigQ>? M2LQRmlvcGmkaYTpc44hd2ZiaIXtZY4hSlOHUDDlfJBz\XO|ZXSgbY4heGyjc33hJI1mdWK{YX7lJJZme2mlbHXzJI9nKFOoMkGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDVGCt[IVx\W6mZX70JHs{UF22YYXyc4Npd2yjdHWgeZB1[WunLDDJR|UxRTBwM988UU4> M4[3UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[1OlI{Lz5{MUm2OVYzOzxxYU6=
Sf21 MXnGeY5kfGmxbjDhd5NigQ>? NHLYSnVKdmirYnn0bY9vKG:oIGPwdoFofWVvRHH3cIV6KHKjdDDCd4VxKGW6cILld5Nm\CCrbjDwcIF{dWFibXXtZpJidmVidnXzbYNt\XNib3[gV4YzOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGFVWC2mZYDlcoRmdnRiW{PIYZRifXKxY3jvcIF1\SC3cIThb4UtKEmFNUC9Nu69VS5? M2TMU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[1OlI{Lz5{MUm2OVYzOzxxYU6=
HepG2 MYfGeY5kfGmxbjDhd5NigQ>? NIDZdYUzOCCqcoO= MkXKRYdwdmm|dDDhZ5Rqfmm2eTDheEBISUx2LYTh[4dm\CCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczD0doFve2GldHn2ZZRqd25iYX\0[ZIhOjBiaILzJIJ6KGKndHGt[4Ft[WO2b4Pp[IF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwNUhOwG0v MljFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|NEG1O|MoRjJ{M{SxOVc{RC:jPh?=
HEK293 MknDSpVv[3Srb36gZZN{[Xl? MV[xPEBpenN? NH;ZWVNVemGwc3HjeIl3[XSrb36gc4YhcHWvYX6gS2FNPC2odYPl[EBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIITyZY5{\mWldHXkJIlvKEiHS{K5N{Bk\WyuczDh[pRmeiBzODDodpMh[nliZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC56zszNMi=> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzFyMki5NUc,OjNzMEK4PVE9N2F-
COS7 M4\GU2Z2dmO2aX;uJIF{e2G7 NGrWflRVemGwc3HjeIl3[XSrb36gc4YhT0GOND3meZNm\CCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIITyZY5{\mWldHXkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV|ch[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMt88UU4> MlHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzM{C5OlQoRjJ|MUOwPVY1RC:jPh?=
THP1 M{fHOmFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MV2xJIhz MUDBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDQUWEucW6mdXPl[EBOS1BvMTDz[YNz\XSrb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJHBOSS2laHHscIVv\2VibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KEWOSWPBMEBKSzVyPUG4Mlg1|ryPLh?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhzMUC5Nkc,OjN6MUGwPVI9N2F-
THP1 NWTtR3BbSW62aXnu[oxidW2jdH;yfUBie3OjeR?= NGi3TpIzKGi{cx?= M4nicmFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hcHWvYX6gWGhROSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHBOSS2rbnT1Z4VlKE2FUD2xJJNm[3KndHnvckBqdmO3YnH0[YQh\m:{IEKgbJJ{KHC{aX;yJJRwKFCPQTDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IFXMTXNCNCCLQ{WwQVE5NjcQvF2u NEC5NJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNVIzPyd-MkS1N|EzOjd:L3G+
HEK293 M1\PT2Z2dmO2aX;uJIF{e2G7 NG\KUnQyOCC3TR?= NVzjWIZpOjRiaILz MonQWJJidnOjY4TpeoF1cW:wIH;mJHBRSVJvZ3HtcYEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> M{S2fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEmwNFkxLz5{NEi5NFA6ODxxYU6=
HEK293 M2qxO2Z2dmO2aX;uJIF{e2G7 NEDtPFIyQCCqcoO= NEHHcHRC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIlv[3WkYYTl[EBnd3JiMUigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlIy|ryPLh?= NEj3fVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzN|g2Oyd-MkWzN|M5PTN:L3G+
COS7 NFq4ZphHfW6ldHnvckBie3OjeR?= MVjUdoFve2GldHn2ZZRqd25ib3[gbJVu[W5iUGDBVodidW2jIHX4dJJme3OnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHnuZ5Vj[XSnZDDveoVzdmmpaISgZpkh\HWjbD3ncI8hdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMt88UU4> M1vjW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm1O|Q6Lz5{NkW5OVc1QTxxYU6=
THP1 NF7QS5BHfW6ldHnvckBie3OjeR?= NVfMeWxPOTBidV2= M3:yWlI1KGi{cx?= MX3VdJJm\3WuYYTpc44hd2ZiQVLDRVEhdVKQQTDlfJBz\XO|aX;uJIlvKGi3bXHuJHRJWDFiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK|IHL5JJFRS1JibXX0bI9lKHKnbHH0bZZmKHSxIHPvcpRzd2x? M1;N[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkKwNFY2Lz5{N{KyNFA3PTxxYU6=
THP1 Ml\OSpVv[3Srb36gZZN{[Xl? MlnoNVAhfU1? MV[yOEBpenN? M{fJVnVxemWpdXzheIlwdiCxZjDBRmNIOSCvUl7BJIV5eHKnc4Ppc44hcW5iaIXtZY4hXEiSMTDj[YxteyCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkheVCFUjDt[ZRpd2RicnXsZZRqfmVidH:gZ49vfHKxbB?= M4fRbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkKwNFY2Lz5{N{KyNFA3PTxxYU6=
COS7 MkHXSpVv[3Srb36gZZN{[Xl? MXW0NkBpenN? NE\FVWhVemGwc3HjeIl3[XSrb36gc4YhT0GOND3meZNm\CCqdX3hckBRWEGUZ3HtcYEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHHmeIVzKDR{IHjyd{BjgSCmdXHsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjYQvF2u MoS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NkCyPFIoRjJ5NU[wNlgzRC:jPh?=
COS7 MnfkSpVv[3Srb36gZZN{[Xl? MWK0NkBpenN? MofFWJJidnOjY4TpeoF1cW:wIHH0JGdidDRiZoXz[YQhWFCDUnfhcY1iKEyERDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHHmeIVzKDR{IHjyd{BjgSCudXPp[oVz[XOnIHHzd4F6NCCHQ{WwQVAvOzMQvF2u MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV4OUG5OUc,Ojd3NkmxPVU9N2F-
COS7 NWPTdppnTnWwY4Tpc44h[XO|YYm= MUi0NkBpenN? MXXUdoFve2GldHn2ZZRqd25ib3[gS4FtPCCodYPl[EBpfW2jbjDQVGFT\2GvbXGgUGJFKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFQzKGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlM5|ryPLh?= M4DhVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUG4PVk1Lz5{N{mxPFk6PDxxYU6=
PC3 MlXUSpVv[3Srb36gZZN{[Xl? MV61NEB2VQ>? Mn;xNlQhcHK| MUPJcoNz\WG|ZTDpckBxOjFqV1HGNUkheHKxdHXpckBmgHC{ZYPzbY9vKGmwIHj1cYFvKFCFMzDj[YxteyCjdDC1NEB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NFH5[lI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVIzOCd-MkizPVUzOjB:L3G+
MDA-MB-231 NULKUYU{TnWwY4Tpc44h[XO|YYm= NFPZOpA2OCC3TR?= NVnve3dLOjRiaILz M4LETGlv[3KnYYPlJIlvKHB{MTjXRWYyMSCycn;0[YlvKGW6cILld5Nqd25iaX6gbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjdDC1NEB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NXjqTpp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizPVUzOjBpPkK4N|k2OjJyPD;hQi=>
HEK293 M4\1cmZ2dmO2aX;uJIF{e2G7 NYXOSWFZOjRiaILz MlT0WJJidnOjY4TpeoF1cW:wIHHjeIl3cXS7IHH0JGdidDRiZoXz[YQh\nWubDDs[Y5ofGhiaIXtZY4hWFCDUnfhcY1iKEyERDDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;MT6x{txONg>? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4NUC5PUc,Ojh2NkWwPVk9N2F-
HEK293 MWXGeY5kfGmxbjDhd5NigQ>? Mo\GOEBpenN? Mle1WJJidnO{ZYDy[ZN{cW:wIHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJo[W2vYTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVF7GZYxxcGFiaX7keYNm\CCQRj3rZZBx[UJicILvcY91\XJiYXP0bZZqfHlicILleJJm[XSnZDDmc5IhPCCqcoOg[o9tdG:5ZXSgZpkhXE6IYXzwbIEhe3SrbYXsZZRqd25iYX\0[ZIhOyCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxRTJ{zszNMi=> NGOyZlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2OVA6QSd-Mki0OlUxQTl:L3G+
SCC15 MlrTR5l1d3SxeHnjbZR6KGG|c3H5 MnPwOVAhfU1? MXOyOEBpenN? M{L3NWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNESzF3IHPlcIx{KHS{YX7z[oVkfGWmIIfpeIghWFCDUnHsdIhiKHOrUl7BJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDC1NEB2VSCjZoTldkAzPCCqcoOgZpkhemW|YYr1dolvKHKnZIXjeIlwdiCjc4PhfS=> NXWzVHdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwN|ExPjNpPkK5NFMyODZ|PD;hQi=>
SCC15 MYDDfZRwfG:6aXPpeJkh[XO|YYm= M1zOfVUxKHWP NXexOIFGOjRiaILz MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTR2MyPSClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJHBRSVKkZYThJJNqWk6DIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCB3MDD1UUBi\nSncjCyOEBpenNiYomgdoV{[Xq3cnnuJJJm\HWldHnvckBie3OjeR?= NEnCe|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUCzNVA3Oyd-MkmwN|ExPjN:L3G+
HepG2 M2\5V2Z2dmO2aX;uJIF{e2G7 NIeycVEzPCCqcoO= MYfB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKFCSUlWgbY5kfWKjdHXkJIZweiB{NDDodpMh[nliZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5{NN88UU4> M{DpbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMECxPFQ3Lz5|MECwNVg1PjxxYU6=
HEK293BENA MUnGeY5kfGmxbjDhd5NigQ>? NUHGS3E5OjRiaILz MmfuWJJidnOjY4TpeoF1cW:wIH;mJGdCVDRvZoXz[YQhcHWvYX6gVHBCWmejbX3hJJRz[W6|ZnXjeIVlKGmwIFjFT|I6O0KHTlGgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KHO2ZXHkfUBodG9vbIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUKuNFU{|ryPLh?= MmX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|NUG5N|MoRjNyM{WxPVM{RC:jPh?=
HEK293 NWL0OWpKTnWwY4Tpc44h[XO|YYm= NXfaUFV2OThiaILz NX\DZpFGXHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJIZ2dGxibHXu[5RpKFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGGodHXyJFE5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZoF{\WRibIXtbY5me2OnbnPlJIF{e2G7LDDFR|UxRTBwMd88UU4> M4HSO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[yO|M6Lz5|MEO2Nlc{QTxxYU6=
293H M{C4bWZ2dmO2aX;uJIF{e2G7 NHTtWWMyPiCqcoO= M1znenRz[W6|YXP0bZZifGmxbjDv[kBISUx2LVTCSEBnfXOnZDDoeY1idiCSUFHS[4FudWFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIV5eHKnc4Pl[EBqdiCXQWOtZoxiKEiHTDCyPVNJKGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNVYhcHK|IH\vcIxwf2WmIHL5JGZTTVRic4Xid5Rz[XSnIHHk[Il1cW:wIHHu[EBu\WG|dYLl[EBi\nSncjCyJIhzeyCkeTDUVk1HWkWWIHHzd4F6NCCHQ{WwQVAvODl6zszNMi=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUC5O{c,OzB2MkmwPVc9N2F-
3T3L1 NW\wWlVvTnWwY4Tpc44h[XO|YYm= NIPhOXUyOCC3TR?= MkfoNlQhcHK| NGHRUGZC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDtc5V{\SB|VEPMNUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCDUEGgcXJPSSCneIDy[ZN{cW:wIHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCVWVLSJIdz\WWwIHT5[UBj[XOnZDDSWE1RS1JiYX7hcJl{cXN? Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OUS0N|IoRjNyNUm0OFMzRC:jPh?=
3T3L1 MV\GeY5kfGmxbjDhd5NigQ>? NYe4cG85OTBidV2= M1fne|I1KGi{cx?= MXvB[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCvb4Xz[UA{XDOOMTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBETDN4IH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkhW1mEUjDndoVmdiCmeXWgZoF{\WRiUmStVGNTKGGwYXz5d4l{ M3;re|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUm0OFMzLz5|MEW5OFQ{OjxxYU6=
3T3L1 MV7GeY5kfGmxbjDhd5NigQ>? MkfXNVAhfU1? NY\zSndrOjRiaILz M4HLdGFod26rc4SgZYN1cX[rdImgZZQhWFCDUnfhcY1iKGmwIH3veZNmKDOWM1yxJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEeudYS0JI1TVkFiZYjwdoV{e2mxbjDheEAyOCC3TTDh[pRmeiB{NDDodpMh[nliU2nCVkBoemWnbjDkfYUh[mG|ZXSgVnQuWEOUIHHuZYx6e2m| M4DkRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUm0OFMzLz5|MEW5OFQ{OjxxYU6=
3T3L1 M{PENWZ2dmO2aX;uJIF{e2G7 NELuV5UyOCC3TR?= MnjRNlQhcHK| NWfybnB1SWexbnnzeEBi[3Srdnn0fUBifCCSUFHS[4FudWFiaX6gcY92e2ViM2SzUFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iYXTpdI9v\WO2aX6gcXJPSSCneIDy[ZN{cW:wIHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCVWVLSJIdz\WWwIHT5[UBj[XOnZDDSWE1RS1JiYX7hcJl{cXN? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV7NESzNkc,OzB3OUS0N|I9N2F-
stem cells MnW4SpVv[3Srb36gZZN{[Xl? NGrjZ2w2KGSjeYO= MnjRTY5lfWO2aX;uJI9nKGGmaYDv[4Vv\XOrczDpckBpfW2jbjDic45mKG2jcoLve{1l\XKrdnXkJI1me2WwY3j5cYFtKHO2ZX2gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[WSrcH;u[YN1cW5icILv[JVkfGmxbjDt[YF{fXKnZDDvckBl[XliNTDpckBxemW|ZX7j[UBw\iCLRGigZpkhTUyLU1GsJGVEPTB;MD6zOe69VS5? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ5Mk[5PEc,OzB4N{K2PVg9N2F-
HEK293T NE\2NHlHfW6ldHnvckBie3OjeR?= MYWxPEBpenN? MkGwWJJidnOjY4TpeoF1cW:wIH;mJIZ2dGxibHXu[5RpKGi3bXHuJHBRSVKpYX3tZVIh\XiycnXzd4VlKGmwIFjFT|I6O1RiY3XscJMh[29vZYjwdoV{e2mwZzDQVHJGKGGodHXyJFE5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5{Nd88UU4> M{HkV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNke2O|QyLz5|ME[3Olc1OTxxYU6=
HEK293T M1G3NWZ2dmO2aX;uJIF{e2G7 M{nQ[FE5KGi{cx?= MmW2WJJidnOjY4TpeoF1cW:wIH;mJINpcW2ncnnjJGdidDRieXXhd5QhTEKGIH\1d4VlNVCSQWLnZY1u[SCOQlSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDjc{1mgHC{ZYPzbY5oKFCSUlWgZYZ1\XJiMUigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlM2|ryPLh?= M4HMR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNke2O|QyLz5|ME[3Olc1OTxxYU6=
HepG2 MXzGeY5kfGmxbjDhd5NigQ>? NH70d2w{OCC3TR?= MX7CbY5lcW6pIHHm[olvcXS7IITvJG5CTjFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKHKnc4DpdoF1cW:wIHH0JFMxKHWP Mlf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB5N{CxOVQoRjNyN{ewNVU1RC:jPh?=
HepG2 NVjGfG5NTnWwY4Tpc44h[XO|YYm= M3;NZVMxKHWP MWHCbY5lcW6pIHHm[olvcXS7IITvJG5CTjFiaX6gbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKHKnc4DpdoF1cW:wIHH0JFMxKHWP Mn7oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB5N{CxOVQoRjNyN{ewNVU1RC:jPh?=
COS7 NV\WN4NpTnWwY4Tpc44h[XO|YYm= NXL3eZJCOzliaILz MofOWJJidnOjY4TpeoF1cW:wIH;mJGdidDRvZoXz[YQhcHWvYX6gVHBCWmejbX3hJJRz[W6|ZnXjeIVlKGmwIFPPV|ch[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBxT0GONT3UT{1xT0x|IHHu[EBxWmWwbnnscIEuS02YIHnuZ5Vj[XSnZDDmc5IhOzliaILzJIJ6KGS3YXygcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygSWM2OD1zLkVOwG0v NV7O[|lHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G2OFgyOjVpPkOxOlQ5OTJ3PD;hQi=>
K562 MnK0SpVv[3Srb36gZZN{[Xl? NU\JXIl7OTBidV2= NH\0WJE4OiCqcoO= NEP4RWNKdmS3Y4Tpc44hd2Zic3Xud4l1cXqjdHnvckB1dyCrbXH0bY5q[i2rbnT1Z4VlKGO7dH;0c5hq[2m2eTDpckBqdWG2aX7pZk1z\XOrc4ThcpQhcHWvYX6gT|U3Oi2LTVHbdn0h[2WubIOgZZN{\XO|ZXSgZZMhcW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigZZQhOTBidV2gZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJFEhfU1iaX3heIlvcWJiYomgdJJweGmmaYXtJIlw\GmmZT;Udol1d25vWEGwNEBlgWViYnHz[YQhTkGFUzDhcoFtgXOrcx?= M{m3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNkS4NVI2Lz5|MU[0PFEzPTxxYU6=
In vivo

Pioglitazone administered orally (0.3-3 mg/kg/d for 7 days) dose dependently reduces hyperglycemia, hyperlipidemia, and hyperinsulinemia in male fatty rats. Pioglitazone improves glucose tolerance and augmentes the glycemic response to exogenous insulin and clearance of plasma triglyceride in rats. [2] Pioglitazone-treated transgenic mice reveals improved muscle strength and body weight, exhibits a delayed disease onset, and survives significantly longer than nontreated SOD1-G93A mice. [3] Pioglitazone markedly decreases hyperglycemia, hyperlipidemia, hyperinsulinemia, and glucoseintolerance characterized as insulin resistant states in these rats and mice. Pioglitazone potentiates insulin-mediated glucose metabolism in the diaphragm and adipose tissues of yellow KK mice and enhanced the glycemic response to exogenous insulin in Zucker fatty rats. [4] Pioglitazone results in a reduction in the number of activated microglia and reactive astrocytes in the hippocampus and cortex of APPV717I transgenic mice. Pioglitazone decreases beta-secretase-1 (BACE1) mRNA and protein levels in APPV717I transgenic mice. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 392.9
Formula

C19H20N2O3S.HCl

CAS No. 112529-15-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05411965 Completed Drug: BR3003(T)|Drug: BR3003B(R1)|Drug: BR3003C(R2) Diabetes Mellitus Type 2 Boryung Pharmaceutical Co. Ltd April 28 2022 Phase 1
NCT04501406 Recruiting Drug: Pioglitazone|Other: Placebo Type 2 Diabetes Mellitus (T2DM)|Nonalcoholic Steatohepatitis University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) December 15 2020 Phase 2
NCT04535700 Unknown status Drug: Pioglitazone 30 mg|Other: standard of care Type 2 Diabetes Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal September 18 2020 Phase 4
NCT00904046 Recruiting Drug: Pioglitazone|Drug: Placebo Uric Acid Kidney Stone Disease University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Takeda Pharmaceuticals North America Inc. September 5 2019 Not Applicable
NCT04671056 Completed Drug: MGL-3196|Drug: Pioglitazone 15mg Healthy Madrigal Pharmaceuticals Inc. November 9 2018 Phase 1
NCT03501277 Completed Drug: Alogliptin|Drug: Pioglitazone|Drug: SYR-322-4833 BL Healthy Volunteers Takeda May 26 2018 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-11-29)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pioglitazone HCl | Pioglitazone HCl supplier | purchase Pioglitazone HCl | Pioglitazone HCl cost | Pioglitazone HCl manufacturer | order Pioglitazone HCl | Pioglitazone HCl distributor